



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: **Pratt**

Application No. **10/623,577**

Group Art Unit: **1614**

Filed: **July 22, 2003**

Examiner: **J. Anderson**

For: **Liquid Dosage Formulations of Donepezil**

Docket: 61368-223339 (BNAG-002-C4US)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Information Disclosure Statement

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the document listed on the attached PTO/SB/08A Form, a copy of which is attached hereto. A copy of the published PCT applications are also submitted herewith.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

This Information Disclosure Statement is being filed after the mailing date of a first office action on the merits, but before a Notice of Allowance or final Office Action on the merits. The Commissioner is authorized to charge the fee of \$180 to Deposit Account No. 22-0261. The Commissioner is authorized to charge any necessary fees or credit any overpayments to Deposit Account No. 22-0261.

Applicants respectfully request that the PTO return an initialed copy of the PTO/SB/08A Form with the next communication from the Office.

Respectfully submitted,

Edward D. Grief
Registration No. 38,898

Date: September 28, 2007
Venable LLP
575 7th Street, NW
Washington, DC 20004
Phone: 202-344-4382

10/31/2007 TADD01 00000007 220261 10623577
02 FC:1806 180.00 DA